Eli Lilly has initiated legal action against four telehealth companies for allegedly distributing illegal copies of its weight loss drug, Zepbound. The drug, which contains tirzepatide, faced shortages that led compounding pharmacies to create substitutes, allowing patients without insurance access to affordable alternatives. However, with the shortage resolved, Lilly is moving to enforce laws against continued sales of these compounded versions, emphasizing that such practices are unlawful and endanger patient safety. The lawsuits target specific telehealth companies and underscore the urgency of addressing deceptive practices in the pharmaceutical market.
Eli Lilly is suing four telehealth companies for selling illegal copies of its weight-loss drug Zepbound, which is based on the active ingredient tirzepatide.
Compounding pharmacies filled the gap during the Zepbound shortage, selling cheaper tirzepatide substitutes, but Eli Lilly is now taking legal action to stop these practices.
Collection
[
|
...
]